PDL BioPharma Profile

2.93
USD 0.05  1.74%
76%
70%

PDL BioPharma exotic insider transaction detected

PDL BioPharma insider trading alert for general transaction of common stock by Klein Joseph Iii, the corporate stakeholder, on April 16, 2018. This event was filed by Pdl Biopharma Inc with SEC on 2009-11-06. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

PDL BioPharma Summary

PDL BioPharma is an interesting company.? They really do not make anything.? Instead, the finance patents within the pharma industry, providing financial monetization of royalty streams to companies and academic institutions.? Their market capitalization is $365 million and the stock is trading at $2.20 per share. ? Basically, what the company does is it finds patents that an institution or company has filed and then PDLI monetizes that patent.? Then, the company licenses the patent out taking in a spread between what the company pays to the patent holder and the fees collected by companies using the patent.? They are a middleman for the pharma patent industry. ? ? [more]
PDL BioPharma (PDLI) is traded on NASDAQ in USA. It is located in NEVADA, U.S.A and employs 87 people. PDL BioPharma is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 446.05 M. PDL BioPharma conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 153.81 M outstanding shares of which 19.07 M shares are at this time shorted by private and institutional investors with about 9.16 trading days to cover. PDL BIOPHARMA INC currently holds about 532.11 M in cash with 40.62 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.46 which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check PDL BioPharma Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Below OddsHorizonTargetAbove Odds
about 64.96%30 days 2.93  about 34.87%
Based on normal probability distribution, the odds of PDL BioPharma to move above current price in 30 days from now is about 34.87% (This PDL BioPharma probability density function shows the probability of PDL BioPharma Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Acadian Asset Management LlcCommon Shares4.7 M14 M
Bank Of MontrealCommon Shares1.1 M3.1 M
Ascend Capital LlcDebt43.8 M43.7 M
View PDL BioPharma Diagnostics

Selected PDL BioPharma Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

PDL BioPharma Against Markets

Risk Adjusted
Performance Score (0 to 100)
6 
Chance of
Financial Distress (0 to 100%)
< 41% 
Equity ratings for PDL BioPharma are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. PDL BioPharma operates under Biotechnology classification in USA and traded on NASDAQ. It employs 87 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NamePDL BioPharma
President CEO, DirectorJohn McLaughlinView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
LocationNEVADA, U.S.A
Business Address932 Southwood Boulevard
ExchangeNASDAQ
CIK Number00882104.0
CUSIP69329Y104
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.pdl.com
Contact Number775 832 8500
CurrencyUSD - US Dollar

Recommendations

PDL BioPharma Analyst Recommendations
Target PriceAdvice# of Analysts
3.5Buy2Odds
PDL BioPharma current and past analyst recommendations published by number of research institutions as well as average analyst consensus
PDL BioPharma Analyst Advice  

Earnings

PDL BioPharma Earnings Estimates
EPSEstimate Date
Quarterly Estimate0.13March 1, 2017
PDL BioPharma normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

PDL BioPharma Corporate Directors
Harold Selick Independent Director, Ph.D
David Gryska Independent Director, MBA
Paul Sandman Independent Director
Additionally take a look at Your Equity Center. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.